Tenderwize
Zurück zur Suche

Open-House Supply Agreement for Therapy Allergens for Subcutaneous Immunotherapy

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene zur subkutanen Immuntherapie, ATC V01AA02

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

48 / 100

Risikofaktoren

Contract documents must be submitted through the DTVP communications area and not through the offer area; using the wro...

Participation is limited to pharmaceutical companies and requires a signed reliability declaration; missing this would...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive open-house supply arrangement for therapy allergens for subcutaneous immunotherapy (ATC V01AA02).
  • Contract terms are pre-set and not individually negotiable.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement by AOK Bayern for pharmaceutical products (therapy allergens for subcutaneous immunotherapy, ATC V01AA02). It is explicitly described as not a standard competitive procurement, with identical non-exclusive contracts offered to all interested pharmaceutical companies meeting the stated suitability requirement. No contract value is provided. Submission is through DTVP or by paper originals in duplicate, with bilingual constraint to German and mandatory German translation for non-German documents. The notice is highly specific on contract start/end timing and monthly cut-off dates.

Risiken

Contract documents must be submitted through the DTVP communications area and not through the offer area; using the wro...

Participation is limited to pharmaceutical companies and requires a signed reliability declaration; missing this would...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contractual partners.

Administrative

  • Submit a signed reliability self-declaration.
  • Submit the signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House Supply Agreement for Therapy Allergens for Subcutaneous Immunotherapy

Open-house non-exclusive supply contract for therapy allergens for subcutaneous immunotherapy (ATC V01AA02). Scope is defined in the contract and related annexes downloadable from the tender documents. The notice says only pharmaceutical companies may become contractual partners. Lot information is from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Frist

Deadline Mar 03, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
179863-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30